|
|
Post by wgreystone on May 22, 2017 12:27:33 GMT -5
I hope someday OneDrop can start to include Afrezza as a correction dose in their subscription plan. It will not increase the cost by much, but will have a large number of patients get chance to try out Afrezza.
|
|
|
|
Post by agedhippie on May 22, 2017 13:13:22 GMT -5
Unfortunately, I didn't see any mention of Afrezza in the article. Is that the same trial? I would expect to have seen some mention of the Apple Watch since that was the whole point of the trial. I think this is a different trial. |
|
|
|
Post by dejude42 on May 22, 2017 15:32:08 GMT -5
|
|
|
|
Post by promann on May 22, 2017 16:21:41 GMT -5
I did not know he was a type 2 are you sure? That's very interesting and also I wonder if he's using Afrezza. |
|
|
|
Post by liane on May 22, 2017 16:30:06 GMT -5
I've never heard he was diabetic either.
|
|
|
|
Post by suebeeee1 on May 22, 2017 16:55:07 GMT -5
He most probably isn't a diabetic. This is from the article:
"By focusing the device on its use in people without diabetes, it would enable technology companies to develop their products without the risk of harm and without the regulatory hurdles to cross.
If the products are successful, it could allow problems to be ironed out before they are submitted for FDA approval. For now, we will continue to watch this space for new developments in the world of the giant tech companies and diabetes."
So, if I had to guess, I'd say he is part of the group wearing it to test it before submitting to the FDA.
|
|
|
|
Post by straightly on May 22, 2017 17:56:21 GMT -5
He most probably isn't a diabetic. This is from the article: "By focusing the device on its use in people without diabetes, it would enable technology companies to develop their products without the risk of harm and without the regulatory hurdles to cross. If the products are successful, it could allow problems to be ironed out before they are submitted for FDA approval. For now, we will continue to watch this space for new developments in the world of the giant tech companies and diabetes." So, if I had to guess, I'd say he is part of the group wearing it to test it before submitting to the FDA. Or just stick it to FDA? I am not aware that IWatch/fitbit etc are trying to submit their heart beat sensors, or did I miss it? This is "life changing", when was last time FDA had to do with that? |
|
|
|
Post by agedhippie on May 23, 2017 6:49:45 GMT -5
Or just stick it to FDA? I am not aware that IWatch/fitbit etc are trying to submit their heart beat sensors, or did I miss it? This is "life changing", when was last time FDA had to do with that? How many people wear iWatch and Fitbits as heart monitors for medical reasons and not just interest? If you are wearing a CGM it's not just for idle interest because in that role it has no purpose. It has to be medical device grade which means FDA approval. Without FDA approval it's just a toy because there is no assurance about accuracy. |
|
|
|
Post by peppy on May 23, 2017 7:09:34 GMT -5
Or just stick it to FDA? I am not aware that IWatch/fitbit etc are trying to submit their heart beat sensors, or did I miss it? This is "life changing", when was last time FDA had to do with that? How many people wear iWatch and Fitbits as heart monitors for medical reasons and not just interest? If you are wearing a CGM it's not just for idle interest because in that role it has no purpose. It has to be medical device grade which means FDA approval. Without FDA approval it's just a toy because there is no assurance about accuracy. Apple CEO Tim Cook has tried using a glucometer to track his blood sugar. So I decided to give it a shot, too.
Millions of people with diabetes monitor their glucose levels on a daily basis. Some are even tracking it continuously. But in Silicon Valley, the trend is now spreading to tech workers who don't have the disease, but feel they'll more easily avoid sugary treats if they can visualize the data. Some are reporting dramatic results with weight loss and increased productivity. www.cnbc.com/2017/05/22/human-guinea-pig-tracking-blood-sugar.html
*It's the new thing. It is in. It is hip. I want that. I have to have it. We eat everyday, multiple times a day, weeeeeeeeeeeeeeee.
|
|
|
|
Post by sportsrancho on May 23, 2017 9:00:36 GMT -5
|
|
|
|
Post by bigkid53 on May 23, 2017 11:01:50 GMT -5
Woke up this morning thinking about the possibility of selling Afrezza on line with or without One Touch. F irst we need FDA approval. Assuming we can get it , what are the possibities. Currently you can one months supply from dis counters for about $230. Assuming middleman markups of about $50,let's say Mannkind's wholesale price is about $180 or $2160per year. To many people that would be a lot of money without insurance discounts. Let me posit that there among the millions of diabetics in the US, that there are a minimum of 100,000 middle and upper class diabetics that would willingly pay ß2000 a tear to receive the benefits of Afrezza. 2160 × 100,000 = $216M. Also sales could come from other countries. At a ten time to sales multiplier that is over a 2 billion $ market cap or $20 share price. This post is just food for thought and further dicussion. I realize that there are many steps that have to occur before t his could happen.
|
|
|
|
Post by brotherm1 on May 23, 2017 11:35:36 GMT -5
I see the potential for good long-term usage data on Afrezza. Especially if combined with a bluetooth enabled inhaler and the Bluetooth blood glucose meter already a part of One-Drop. I like seeing tweets of people getting great control, but hard data will push the industry Is the Bluetooth Inhaler actually being used yet by any Afrezza patients? |
|
|
|
Post by dreamboatcruise on May 23, 2017 12:10:27 GMT -5
I see the potential for good long-term usage data on Afrezza. Especially if combined with a bluetooth enabled inhaler and the Bluetooth blood glucose meter already a part of One-Drop. I like seeing tweets of people getting great control, but hard data will push the industry Is the Bluetooth Inhaler actually being used yet by any Afrezza patients? If you are talking about Bluhale it is a device about profiling the air volume inhaled while dosing. Hopefully, and supposedly, that is not something that is needed as the Dreamboat inhaler has been verified to deliver consistent doses for anyone that can take a normal full breath regardless of the exact air flow. Bluhale was never intended to be used during the normal course of using Afrezza. If you are talking about the new device mentioned in the announcement about the MOU with One Drop... that does not exist yet. I suspect the utility of it may not be deemed cost effective. The amount of effort required to pull up the app and push a button that one has just dosed insulin would be hard to justify cost of putting bluetooth into a disposable device. Bluetooth is cheap, but not free. |
|
|
|
Post by mnholdem on May 23, 2017 14:08:05 GMT -5
You're right that the BluHale itself wouldn't do the trick, but I would think that a Bluhale-type device could be designed with transmitter and three buttons to select the cartridge unit size. The transmitter would be a snap-on like the BluHale and you wouldn't throw it away. Simply snap it onto a new cartridge.
Ideally, the cartridges would be re-design to utilize raised-dots (like braille) on the plastic housing which would tell the communicator what cartridge is currently inserted. None of this is difficult to engineer these days.
|
|
|
|
Post by dreamboatcruise on May 23, 2017 14:26:14 GMT -5
You're right that the BluHale itself wouldn't do the trick, but I would think that a Bluhale-type device could be designed with transmitter and three buttons to select the cartridge unit size. The transmitter would be a snap-on like the BluHale and you wouldn't throw it away. Simply snap it onto a new cartridge. Ideally, the cartridges would be re-design to utilize raised-dots (like braille) on the plastic housing which would tell the communicator what cartridge is currently inserted. None of this is difficult to engineer these days. If it were snap-on, as the Bluhale is, I would question whether most users would want to have their inhaler be bulkier merely for the convenience of not having to pull their phone out if they wished to track the exact time they took insulin. After all, at any given moment of the day, your average American is likely to already have their phone out and using it. Granted, I suspect the snap-on could be made less bulky than Bluhale... but I think if I were a user and wanting to track insulin, I'd opt to do it myself on the phone vs any increase in bulk (the perspective of a guy that would likely carry the inhaler in my pocket). That said, I seem to remember the PR on the MOU indicated that they were investigating having the bluetooth in a disposable form. I remember when a few years ago people were talking about the notion that all pill bottles would soon have bluetooth caps to record when a patient opened it. Not that it wouldn't have some marginal utility (I'm not yet terribly old and sometimes have trouble remembering if I actually took my once a day pill), but cost will likely dictate that pill bottles will generally remain dumb. |
|
